Pale Fire Capital SE Acquires 1,246,673 Shares of Heron Therapeutics, Inc. $HRTX

Pale Fire Capital SE increased its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 84.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,716,328 shares of the biotechnology company’s stock after purchasing an additional 1,246,673 shares during the period. Heron Therapeutics makes up 0.2% of Pale Fire Capital SE’s portfolio, making the stock its 26th biggest position. Pale Fire Capital SE owned approximately 1.44% of Heron Therapeutics worth $2,173,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. SG Americas Securities LLC raised its holdings in Heron Therapeutics by 39.1% during the 4th quarter. SG Americas Securities LLC now owns 24,377 shares of the biotechnology company’s stock worth $32,000 after buying an additional 6,858 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in shares of Heron Therapeutics by 5.1% in the second quarter. The Manufacturers Life Insurance Company now owns 241,048 shares of the biotechnology company’s stock valued at $499,000 after buying an additional 11,716 shares during the period. B. Riley Wealth Advisors Inc. bought a new stake in shares of Heron Therapeutics during the second quarter worth $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Heron Therapeutics by 19.3% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,756 shares of the biotechnology company’s stock worth $173,000 after acquiring an additional 13,544 shares in the last quarter. Finally, Advisory Services Network LLC raised its holdings in shares of Heron Therapeutics by 2,383.4% during the fourth quarter. Advisory Services Network LLC now owns 18,874 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 18,114 shares during the period. 80.01% of the stock is currently owned by institutional investors and hedge funds.

Heron Therapeutics Price Performance

NASDAQ HRTX opened at $0.46 on Friday. The firm’s 50 day moving average is $0.53 and its 200-day moving average is $0.90. The company has a quick ratio of 1.51, a current ratio of 2.53 and a debt-to-equity ratio of 17.51. The company has a market capitalization of $86.27 million, a PE ratio of -2.53 and a beta of 1.65. Heron Therapeutics, Inc. has a 12-month low of $0.38 and a 12-month high of $1.93.

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Monday, May 11th. The biotechnology company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.01). The business had revenue of $34.71 million for the quarter, compared to analyst estimates of $36.72 million. Heron Therapeutics had a negative return on equity of 7,747.30% and a negative net margin of 20.53%. Equities research analysts anticipate that Heron Therapeutics, Inc. will post -0.09 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently commented on HRTX. HC Wainwright cut their price objective on shares of Heron Therapeutics to $2.00 and set a “buy” rating on the stock in a research report on Wednesday, June 3rd. Wall Street Zen downgraded Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Zacks Research lowered Heron Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, April 27th. Needham & Company LLC lowered Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, June 2nd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heron Therapeutics in a research report on Friday, July 17th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $2.50.

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.